Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report.

Danzhen Ou, Yijing Li, Jingjing Wu, Shunjie Ou, Fangwei Xie

Abstract readCase Reports

In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danzhen OuDepartment of Tumor Integrated Therapy, The Fuzhou First General Hospital Afffliated with Fujian Medical University No. 190, Dadao Road, Taijiang District, Fuzhou 350009, Fujian, China.

Yijing LiDepartment of Tumor Integrated Therapy, The Fuzhou First General Hospital Afffliated with Fujian Medical University No. 190, Dadao Road, Taijiang District, Fuzhou 350009, Fujian, China.

Jingjing WuDepartment of Tumor Integrated Therapy, The Fuzhou First General Hospital Afffliated with Fujian Medical University No. 190, Dadao Road, Taijiang District, Fuzhou 350009, Fujian, China.

Shunjie OuDepartment of Tumor Integrated Therapy, The Fuzhou First General Hospital Afffliated with Fujian Medical University No. 190, Dadao Road, Taijiang District, Fuzhou 350009, Fujian, China.

Fangwei XieDepartment of Tumor Integrated Therapy, The Fuzhou First General Hospital Afffliated with Fujian Medical University No. 190, Dadao Road, Taijiang District, Fuzhou 350009, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We reported a case of advanced hepatocellular carcinoma (HCC) in a patient who relapsed after first-line chemoimmunotherapy. Remarkably, the combination of H101 oncolytic virotherapy and tislelizumab successfully induced an abscopal effect. Following this treatment, the patient achieved a 24-month survival period, accompanied by complete regression of distant metastatic lesions. Distinct tumor responses were observed at different sites following H101 injection. Lesions showing regression demonstrated higher infiltration of CD3

Indexed as

abscopal effectH101HCCintra-tumoral injectionreverse immune resistance

Identifiers

PMID40667543

DOI10.62347/VSQY6496

PMCPMC12256427

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.